Novavax should have potential

6
Comment
Favorite

Williamting
2021-08-22

Novavax should have potential for great growth USA pension funds have taken up some stakes in thiscounter.??

4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025

Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade. Key P

4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":832291331,"tweetId":"832291331","gmtCreate":1629633942923,"gmtModify":1676530083004,"author":{"id":3573440441801146,"idStr":"3573440441801146","authorId":3573440441801146,"authorIdStr":"3573440441801146","name":"Williamting","avatar":"https://static.tigerbbs.com/93f4f81864155daee4e7c8aac19c8f21","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Novavax should have potential for great growth USA pension funds have taken up some stakes in thiscounter.??</body></html>","htmlText":"<html><head></head><body>Novavax should have potential for great growth USA pension funds have taken up some stakes in thiscounter.??</body></html>","text":"Novavax should have potential for great growth USA pension funds have taken up some stakes in thiscounter.??","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/832291331","repostId":1122814365,"repostType":2,"repost":{"id":"1122814365","kind":"news","pubTimestamp":1629292156,"share":"https://www.laohu8.com/m/news/1122814365?lang=&edition=full","pubTime":"2021-08-18 21:09","market":"us","language":"en","title":"4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1122814365","media":"Motley Fool","summary":"Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade.\n\nKey P","content":"<blockquote>\n Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade.\n</blockquote>\nKey Points\n<ul>\n <li>Rapid sales growth doesn't always tell you the full story about a company.</li>\n</ul>\nFor the past 12 years, growth stocks have been all the rage on Wall Street -- and with good reason. Historically low lending rates and abundant access to this cheap capital have fueled hiring, innovation, and even acquisitions among fast-paced companies.\nBut for some growth stocks, the expected uptick in revenue is just getting started. According to consensus estimates from Wall Street, the following four hypergrowth stocks are expected to increase their sales by anywhere from 1,100% to more than 4,200% over the next three to five years.\nNovavax: Implied sales growth of 1,337% by 2025\nBiotech stocksare always a good bet to see their sales rocket from zero to hero with their first drug approval. Clinical-stage drug developerNovavax(NASDAQ:NVAX)is expected to do even more with the expected emergency-use authorization (EUA) approval of its coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373. Per Wall Street, Novavax could see sales catapult from nearly $476 million in 2020 to roughly $6.84 billion by 2025.\nTo date, Novavax has run two large-scale clinical trials for its COVID-19 vaccine. In March, phase 3 trial data from the U.K. showed a vaccine efficacy (VE) of 89.7%. Data from the second phase 3 study, conducted in the U.S. and Mexico, was released in June and demonstrated a very similar VE of 90.4%. Theeffectiveness of Novavax's vaccinemakes it very likely that it'll soon be authorized in developed markets like the U.S., U.K., and Europe, and could play a key role in emerging markets, as well. Novavax may also push vaccines with lower perceived efficacy --Johnson &amp; Johnson&nbsp;andAstraZeneca&nbsp;-- to the back of the line.\nThe only real drag for Novavax shareholders has been the company'snumerous delays in filing for EUA. Initially expected to go after EUA in the U.S. in the second quarter, the company now anticipates filing the appropriate paperwork during the fourth quarter. There have also been concerns about the company's timeline to ramp up vaccine production to full capacity.\nNevertheless, these delays of a quarter or two aren't going to hamper Novavax's longer-term prospects, which appear to be buoyed by the development of disease variants. The company's ability to quickly develop a vaccine, as well as its early stage research that combines influenza and COVID-19 into a single booster shot, should keep Novavax on the map for a long time to come.\nBlink Charging: Implied sales growth of 2,352% by 2025\nAnother growth stocks with (pun intended) supercharged sales growth potential over the next five years isBlink Charging(NASDAQ:BLNK). Blink provides electric-vehicle (EV) charging infrastructure, as well as owns charging station networks.\nThe logic behind Blink's growth is pretty easy to wrap your hands around. Last year, 1.8% of all new vehicles registered in the U.S. were EVs. But by 2025, an IHS Markit study predicts that 10% of all new vehicle registrations will be EVs.&nbsp; As the electrification of America takes shape, demand for charging infrastructureis only going to tick higher. There should be plenty of room for ancillary EV players like Blink Charging to take advantage of this trend for decades to come.\nBased on Wall Street's consensus estimate, Blink Charging is expected to grow its sales from a reported $6.2 million in 2020 to $152 million by mid-decade. That's a 2,352% revenue increase, for those of you keeping score at home.\nHowever, Blink's future is far from certain. Its current market cap places it at a multiple of 9 times estimated sales for 2025, and it's not particularly close to generating a profit. The company alsodoesn't appear to be investing any of its cash into research and development.&nbsp; With no true means to stand out, it's quite possible Blink Charging gets left in the dust by its competition.\nJushi Holdings: Implied sales growth of 1,101% by 2024\nU.S.marijuana stocks&nbsp;are a fantastic bet to deliver triple-digit aggregate sales growth over the next three to five years as new states legalize pot and already legalized states benefit from organic growth. But you can forget about triple-digit sales growth with multistate operatorJushi Holdings(OTC:JUSHF). According to estimates from&nbsp;FactSet, Jushi's projected push to $969 million in annual revenue by 2024 would mark a 1,101% increase from the $80.7 million in sales generated last year.\nOperating in the highly lucrative U.S. market is bound to give Jushi a boost. We've already seen 36 states legalize cannabis in some capacity, 18 of which have passed legislation to allow for the consumption and/or retail sale of adult-use weed. If New Frontier Data's latest report on the U.S. pot industry proves accurate, legal weed sales could grow by an annualized average of 21% through 2025, ultimately hitting north of $41 billion.\nJushi is a relatively small player in the cannabis space, for the time being. It has 20 operating dispensaries, but will likely end the year closer to 30, inclusive of organic openings and acquisitions. The company's&nbsp;core focus is on a trio of limited-license states: Virginia, Pennsylvania, and Illinois. The former issues licenses based on jurisdiction, whereas the latter two limit the aggregate number of retail and cultivation licenses assigned. By targeting limited-license states, Jushi will be somewhat protected from competitors with deeper pockets.\nSimilar to Novavax, Jushi is expected to turn the corner to recurring profitability in 2022. It looks to be one of the&nbsp;biggest bargains in the cannabis industry.\nRiot Blockchain: Implied sales growth of 4,231% by 2023\nThe last hypergrowth stock expected to deliver insane revenue growth in the coming years is&nbsp;cryptocurrency miningcompanyRiot Blockchain(NASDAQ:RIOT). After reporting just $12.1 million in full-year sales in 2020, Wall Street is expecting Riot to bring in $524 million in revenue by 2023. That's a greater than 4,200% sales increase in just three years.\nCryptocurrency miners are people or companies that use high-powered computers to solve complex mathematical equations to validate groups of transactions known as a block. For doing so, crypto miners are paid a block reward. In Riot's case, its revenue is soaring becauseit's building up its farmto mine&nbsp;Bitcoin(CRYPTO:BTC), the world's largest digital currency by market cap. The Bitcoin block reward equates to 6.25 Bitcoin, which is worth about $287,000, as of August 15.\nAs of the end of July, Riot Blockchain held approximately 2,687 Bitcoin on its balance sheet (these are tokens the company has mined since inception), with plans to have 25,946 Antminers in operation by early September. The goal for Riot Blockchain is to have its full fleet of miners (81,146 Antminers) in operation by the fourth quarter of 2022.\nWhile the sales growth in Bitcoin mining stocks is undeniable, therisks are hard to overlook, as well. Instead of being reliant on innovation, Riot is entirely dependent on investor sentiment in Bitcoin and the price of the token. We've also witnessed three declines of at least 80% in Bitcoin over the past decade, which could potentially crush Riot Blockchain's operating model.\nBut the real concern is that there's no barrier to entry in the crypto mining space, and Bitcoin block rewards will halve to 3.125 tokens by 2024. This is a highly competitive space with decreasing rewards.","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Hypergrowth Stocks Expected to Increase Sales 1,100% (or More) by 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-18 21:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/18/4-hypergrowth-stocks-increase-sales-1100-by-2025/>Motley Fool</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nRevenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade.\n\nKey Points\n\nRapid sales growth doesn't always tell you the full story about a company.\n\nFor the past 12 ...\n\n<a href=\"https://www.fool.com/investing/2021/08/18/4-hypergrowth-stocks-increase-sales-1100-by-2025/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","RIOT":"Riot Platforms","BLNK":"Blink Charging"},"source_url":"https://www.fool.com/investing/2021/08/18/4-hypergrowth-stocks-increase-sales-1100-by-2025/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122814365","content_text":"Revenue for these fast-paced stocks should skyrocket between 1,100% and 4,200% by mid-decade.\n\nKey Points\n\nRapid sales growth doesn't always tell you the full story about a company.\n\nFor the past 12 years, growth stocks have been all the rage on Wall Street -- and with good reason. Historically low lending rates and abundant access to this cheap capital have fueled hiring, innovation, and even acquisitions among fast-paced companies.\nBut for some growth stocks, the expected uptick in revenue is just getting started. According to consensus estimates from Wall Street, the following four hypergrowth stocks are expected to increase their sales by anywhere from 1,100% to more than 4,200% over the next three to five years.\nNovavax: Implied sales growth of 1,337% by 2025\nBiotech stocksare always a good bet to see their sales rocket from zero to hero with their first drug approval. Clinical-stage drug developerNovavax(NASDAQ:NVAX)is expected to do even more with the expected emergency-use authorization (EUA) approval of its coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373. Per Wall Street, Novavax could see sales catapult from nearly $476 million in 2020 to roughly $6.84 billion by 2025.\nTo date, Novavax has run two large-scale clinical trials for its COVID-19 vaccine. In March, phase 3 trial data from the U.K. showed a vaccine efficacy (VE) of 89.7%. Data from the second phase 3 study, conducted in the U.S. and Mexico, was released in June and demonstrated a very similar VE of 90.4%. Theeffectiveness of Novavax's vaccinemakes it very likely that it'll soon be authorized in developed markets like the U.S., U.K., and Europe, and could play a key role in emerging markets, as well. Novavax may also push vaccines with lower perceived efficacy --Johnson & Johnson andAstraZeneca -- to the back of the line.\nThe only real drag for Novavax shareholders has been the company'snumerous delays in filing for EUA. Initially expected to go after EUA in the U.S. in the second quarter, the company now anticipates filing the appropriate paperwork during the fourth quarter. There have also been concerns about the company's timeline to ramp up vaccine production to full capacity.\nNevertheless, these delays of a quarter or two aren't going to hamper Novavax's longer-term prospects, which appear to be buoyed by the development of disease variants. The company's ability to quickly develop a vaccine, as well as its early stage research that combines influenza and COVID-19 into a single booster shot, should keep Novavax on the map for a long time to come.\nBlink Charging: Implied sales growth of 2,352% by 2025\nAnother growth stocks with (pun intended) supercharged sales growth potential over the next five years isBlink Charging(NASDAQ:BLNK). Blink provides electric-vehicle (EV) charging infrastructure, as well as owns charging station networks.\nThe logic behind Blink's growth is pretty easy to wrap your hands around. Last year, 1.8% of all new vehicles registered in the U.S. were EVs. But by 2025, an IHS Markit study predicts that 10% of all new vehicle registrations will be EVs.  As the electrification of America takes shape, demand for charging infrastructureis only going to tick higher. There should be plenty of room for ancillary EV players like Blink Charging to take advantage of this trend for decades to come.\nBased on Wall Street's consensus estimate, Blink Charging is expected to grow its sales from a reported $6.2 million in 2020 to $152 million by mid-decade. That's a 2,352% revenue increase, for those of you keeping score at home.\nHowever, Blink's future is far from certain. Its current market cap places it at a multiple of 9 times estimated sales for 2025, and it's not particularly close to generating a profit. The company alsodoesn't appear to be investing any of its cash into research and development.  With no true means to stand out, it's quite possible Blink Charging gets left in the dust by its competition.\nJushi Holdings: Implied sales growth of 1,101% by 2024\nU.S.marijuana stocks are a fantastic bet to deliver triple-digit aggregate sales growth over the next three to five years as new states legalize pot and already legalized states benefit from organic growth. But you can forget about triple-digit sales growth with multistate operatorJushi Holdings(OTC:JUSHF). According to estimates from FactSet, Jushi's projected push to $969 million in annual revenue by 2024 would mark a 1,101% increase from the $80.7 million in sales generated last year.\nOperating in the highly lucrative U.S. market is bound to give Jushi a boost. We've already seen 36 states legalize cannabis in some capacity, 18 of which have passed legislation to allow for the consumption and/or retail sale of adult-use weed. If New Frontier Data's latest report on the U.S. pot industry proves accurate, legal weed sales could grow by an annualized average of 21% through 2025, ultimately hitting north of $41 billion.\nJushi is a relatively small player in the cannabis space, for the time being. It has 20 operating dispensaries, but will likely end the year closer to 30, inclusive of organic openings and acquisitions. The company's core focus is on a trio of limited-license states: Virginia, Pennsylvania, and Illinois. The former issues licenses based on jurisdiction, whereas the latter two limit the aggregate number of retail and cultivation licenses assigned. By targeting limited-license states, Jushi will be somewhat protected from competitors with deeper pockets.\nSimilar to Novavax, Jushi is expected to turn the corner to recurring profitability in 2022. It looks to be one of the biggest bargains in the cannabis industry.\nRiot Blockchain: Implied sales growth of 4,231% by 2023\nThe last hypergrowth stock expected to deliver insane revenue growth in the coming years is cryptocurrency miningcompanyRiot Blockchain(NASDAQ:RIOT). After reporting just $12.1 million in full-year sales in 2020, Wall Street is expecting Riot to bring in $524 million in revenue by 2023. That's a greater than 4,200% sales increase in just three years.\nCryptocurrency miners are people or companies that use high-powered computers to solve complex mathematical equations to validate groups of transactions known as a block. For doing so, crypto miners are paid a block reward. In Riot's case, its revenue is soaring becauseit's building up its farmto mine Bitcoin(CRYPTO:BTC), the world's largest digital currency by market cap. The Bitcoin block reward equates to 6.25 Bitcoin, which is worth about $287,000, as of August 15.\nAs of the end of July, Riot Blockchain held approximately 2,687 Bitcoin on its balance sheet (these are tokens the company has mined since inception), with plans to have 25,946 Antminers in operation by early September. The goal for Riot Blockchain is to have its full fleet of miners (81,146 Antminers) in operation by the fourth quarter of 2022.\nWhile the sales growth in Bitcoin mining stocks is undeniable, therisks are hard to overlook, as well. Instead of being reliant on innovation, Riot is entirely dependent on investor sentiment in Bitcoin and the price of the token. We've also witnessed three declines of at least 80% in Bitcoin over the past decade, which could potentially crush Riot Blockchain's operating model.\nBut the real concern is that there's no barrier to entry in the crypto mining space, and Bitcoin block rewards will halve to 3.125 tokens by 2024. This is a highly competitive space with decreasing rewards.","news_type":1},"isVote":1,"tweetType":1,"viewCount":366,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["NVAX"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":92,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}